PMC9314645_01
Levels of HBV DNA during CD7 CAR-T therapy bridging to HSCT.
fimmu-13-931452-g001.jpg
PMC9314645_01_fimmu-13-931452-g001.jpg
f1
The changes in HBV DNA during treatment are illustrated in  Figure 1 .
PCR was used to monitor the change trend of CD7 CAR T-cell count in vivo during CAR-T and transplantation.
fimmu-13-931452-g002.jpg
PMC9314645_01_fimmu-13-931452-g002.jpg
f2
Figure 2 ). Four and a half months after transplantation, abnormal T lymphocytes expressing CD7-CD5+ were detected by flow cytometry, but the patient was still in complete remission with full donor chimerism in both bone marrow and CD3+ cells in peripheral blood.
MRD was detected by flow cytometry during CD7 CAR-T therapy bridging to HSCT.
fimmu-13-931452-g003.jpg
PMC9314645_01_fimmu-13-931452-g003.jpg
f3
Half a month after reducing immunosuppressive agents, the flow cytometry of bone marrow turned negative ( Figure 3 ).
Sequential infusion of anti-CD7 CAR-T therapy bridging to HSCT. (A) Levels of WBC and PLT during CAR-T therapy bridging to HSCT. (B) Levels of ALS and AST during CAR-T therapy bridging to HSCT. (C) Levels of TBIL and DBIL during CAR-T therapy bridging to HSCT. (D) Levels of IL-6, TNF-a, IL-10 and CD25 during CAR-T therapy bridging to HSCT.
fimmu-13-931452-g004.jpg
PMC9314645_01_fimmu-13-931452-g004.jpg
f4
Blood indicators (white blood cells, platelets), biochemical indicators (AST, ALT, DBIL, TBIL), and cytokines (interleukin 6, tumor necrosis factor alpha, interleukin 10, soluble CD25, interferon gamma) were all monitored ( Figure 4 ). Engrafted leukocytes survived 18 days after transplantation ( Figure 4A ). TBIL and DBIL in  Figure 4C ). There was a transient increase in transaminase and bilirubin after transplantation. The concentrations of cytokines (interleukin 6, tumor necrosis factor alpha, interleukin 10, soluble CD25, interferon gamma) peaked four days after CD7 CAR-T treatment, consistent with the CRS response, then increased to another peak after HSCT, and fell after that ( Figure 4D ).